Department of Parasitology and Institute of Medical Science, Kangwon National University School of Medicine, Hyoja2-dong, Chunchon, 200-701, Kangwon-do, Republic of Korea.
Parasitol Res. 2011 Nov;109(5):1259-66. doi: 10.1007/s00436-011-2370-z. Epub 2011 Apr 13.
Protein arrays are powerful tools for antibody profiling and vaccine development against infectious agents. In the previous report, we successfully applied an antibody-based protein array for immunoprofiling of Plasmodium vivax infection. Herein, we developed a Ni-NTA surface based protein array to detect immune responses against the recombinant C-terminal region (19 and 42 kDa) of the P. vivax merozoite surface protein 1 (PvMSP1-19 and -42) from sera of vivax malaria patients. The PvMSP1-19 arrays detected P. vivax in 112 of 130 (86.2%; 95% CI, 83.2-89.2%) microscopically positive samples and 2 false positives were obtained among 100 sera samples from healthy subjects (2.0%; 95% CI, 0.6-3.4%). These results were in concordance with results of enzyme-linked immunosorbent assays (ELISA). Kappa values represented excellent agreement for the recombinant PvMSP1-19 protein against sera samples as measured by protein arrays and ELISA (Kappa=0.904, 95% CI: 0.849-0.960). The PvMSP1-42 protein arrays detected antibody response in 100 of 130 microscopically positive samples (76.9%; 95% CI, 72.4-86.8%) and 8 false positives were obtained in 100 healthy subjects (8.0%; 95% CI, 2.7-13.3%). There is no significant difference between the fluorescent intensity of antibody response to PvMSP1-19 and PvMSP1-42 in the positive sera samples (P>0.05). The novel protein array platform may be used for profiling naturally acquired humoral immune responses to P. vivax infection.
蛋白质芯片是用于针对传染性病原体进行抗体分析和疫苗开发的有力工具。在之前的报告中,我们成功地应用了一种基于抗体的蛋白质芯片来进行间日疟原虫感染的免疫分析。在此,我们开发了一种基于 Ni-NTA 表面的蛋白质芯片,用于检测来自间日疟患者血清中针对恶性疟原虫裂殖体表面蛋白 1(PvMSP1-19 和 -42)的重组 C 端区域(19 和 42 kDa)的免疫反应。PvMSP1-19 芯片检测到 130 个显微镜阳性样本中的 112 个(86.2%;95%CI,83.2-89.2%)有感染,在 100 个健康对照者血清样本中得到 2 个假阳性(2.0%;95%CI,0.6-3.4%)。这些结果与酶联免疫吸附试验(ELISA)的结果一致。Kappa 值表示蛋白质芯片和 ELISA 检测重组 PvMSP1-19 蛋白与血清样本之间的一致性非常好(Kappa=0.904,95%CI:0.849-0.960)。PvMSP1-42 蛋白芯片检测到 130 个显微镜阳性样本中的 100 个(76.9%;95%CI,72.4-86.8%)有抗体反应,在 100 个健康对照者中得到 8 个假阳性(8.0%;95%CI,2.7-13.3%)。在阳性血清样本中,PvMSP1-19 和 PvMSP1-42 的抗体反应荧光强度之间没有显著差异(P>0.05)。新型蛋白质芯片平台可用于分析自然获得的针对间日疟原虫感染的体液免疫反应。